Tomoregulin-1 (TMEFF1) is an emerging Type I transmembrane glycoprotein containing two follistatin-like domains and one EGF-like domain. Primarily recognized for its role in inhibiting Nodal signaling through interaction with Cripto-1 (TDGF1), TMEFF1 has become a highly attractive target in oncology—particularly in brain tumors, endometrial cancers, and other solid tumors where Nodal/TGF-beta signaling is dysregulated. Developing therapeutics against TMEFF1 requires precise, conformationally intact reagents to validate target binding, internalization, and pathway modulation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEFF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEFF1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). Sequence Verified. HEK293 Expressed for native glycosylation. |
View TMEFF1 Products |
| Gene Delivery | TMEFF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based binding and flow cytometry assays. |
View TMEFF1 Products |
| Benchmark Ab | Anti-TMEFF1 Biosimilar Antibody Recombinant positive control matching clinical/preclinical benchmark sequences. |
View TMEFF1 Products |
| Validator | TMEFF1 siRNA Set For target knockdown verification and target specificity validation. |
View TMEFF1 Products |
| Related Target A | TDGF1 (Cripto-1) Primary co-receptor interacting with TMEFF1 to modulate Nodal/TGF-beta signaling pathways. |
View TDGF1 Products |
| Related Target B | TMEFF2 (Tomoregulin-2) Homologous family member. Highly critical for off-target selectivity and cross-reactivity screening. |
View TMEFF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native post-translational modifications (PTMs) | HEK293 mammalian expression host ensures correct disulfide bridging and complex N-glycosylation. |
| Subfamily off-target cross-reactivity screening | TMEFF2 homolog proteins available with verified sequences and high purity (>95%) for counter-screening. |
| Lack of standardized positive controls | Clinical-grade benchmark biosimilar antibodies included in the catalog for assay calibration. |
| Assay validation and target knockdown validation | Sequence-verified siRNA pools included to confirm assay sensitivity and target knockdown. |
Live TMEFF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEFF1 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific constructs. As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting brain-penetrant formulations and combination therapies designed to bypass Nodal-mediated drug resistance in glioblastoma and endometrial carcinomas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Pioneers, Oncology Therapeutics | Glioblastoma, Endometrial Cancer | Internalization Assay (Requires highly pure, native ECD-Fc protein to measure receptor-mediated endocytosis) |
| Bispecific Antibodies | Immunotherapy Developers | Solid Tumors, Brain Metastases | Heterodimer Validation (Requires both TMEFF1 and Cripto-1/TDGF1 target proteins for dual-binding affinity validation) |
| Small Molecule Inhibitors | Targeted Therapeutics Corp | Refractory Glioma | Selectivity Assay (Requires recombinant TMEFF1 and TMEFF2 panel screening to rule out off-target effects) |